MCID: PLS009
MIFTS: 49

Plasma Cell Neoplasm

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 15 73
Plasma Cell Dyscrasia 12 73
Paraproteinemias 44 73
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 73
Plasmacytoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:6536
MeSH 44 D010265
SNOMED-CT 68 71390001

Summaries for Plasma Cell Neoplasm

MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to plasmacytoma and myeloma, multiple. An important gene associated with Plasma Cell Neoplasm is MYOM2 (Myomesin 2), and among its related pathways/superpathways are NF-kappaB Signaling and B cell receptor signaling pathway (KEGG). The drugs Aredia and Farydak have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are cellular and hematopoietic system

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
# Related Disease Score Top Affiliating Genes
1 plasmacytoma 32.0 B2M CD38 CD79A IL6 MYC PTPRC
2 myeloma, multiple 30.8 B2M CD19 CD38 IL6 MAEA MYC
3 extramedullary plasmacytoma 30.7 B2M IL6 MYOM2
4 mononeuritis multiplex 30.0 MAG MYOM2
5 peripheral nervous system disease 29.8 IL6 MAG MYOM2
6 lung lymphoma 29.7 CD19 CD79A NCAM1
7 poems syndrome 29.7 IL6 MYOM2
8 leukemia, chronic lymphocytic 29.5 B2M CD19 CD38 PTPRC
9 lymphoma, hodgkin, classic 29.5 CD19 CD79A PTPRC PVT1
10 monoclonal gammopathy of uncertain significance 29.1 B2M CD19 CD38 IL6 MAG MYOM2
11 solitary osseous plasmacytoma 28.6 B2M CD19 CD38 CD79A MAEA MYOM2
12 monoclonal paraproteinemia 12.3
13 refractory plasma cell neoplasm 12.3
14 macroglobulinemia 11.5
15 waldenstrom macroglobulinemia 11.5
16 dysfibrinogenemia 11.2
17 light chain deposition disease 11.2
18 lymphoid interstitial pneumonia 11.1
19 amyloidosis 10.6
20 polyneuropathy 10.6
21 plasma cell leukemia 10.5
22 plasmacytic leukemia 10.3
23 extramedullary soft tissue plasmacytoma 10.3
24 primary plasmacytoma of the bone 10.3
25 indolent myeloma 10.3 B2M MYOM2
26 mononeuritis of upper limb and mononeuritis multiplex 10.3 MAG MYOM2
27 chronic polyneuropathy 10.2 MAG MYOM2
28 streptococcal toxic-shock syndrome 10.2 IL6 MYOM2
29 polyclonal hypergammaglobulinemia 10.2 IL6 MYOM2
30 invasive malignant thymoma 10.2 CD19 CD38
31 subcutaneous panniculitis-like t-cell lymphoma 10.2 MYC NCAM1
32 glomeruloid hemangioma 10.2 MYOM2 PTPRC
33 pericoronitis 10.1 CD19 NCAM1
34 congenital hypogammaglobulinemia 10.1 CD19 CD79A
35 impetigo 10.1 IL6 MYOM2
36 rhinoscleroma 10.1 CD19 NCAM1
37 endometrial small cell carcinoma 10.1 NCAM1 PTPRC
38 human immunodeficiency virus infectious disease 10.1 B2M CD38 IL6
39 motor neuron disease 10.1
40 systemic mastocytosis 10.1
41 fanconi syndrome 10.1
42 mastocytosis 10.1
43 al amyloidosis 10.1
44 b cell prolymphocytic leukemia 10.1 CD19 CD38 MYC
45 amyloid tumor 10.1 B2M MYOM2
46 prolymphocytic leukemia 10.1 CD19 CD38 MYC
47 scleromyxedema 10.1
48 mediastinal cancer 10.1 CD79A NCAM1
49 ovarian lymphoma 10.1 MYC PTPRC
50 bladder lymphoma 10.1 CD19 CD79A

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Monoclonal Paraproteinemia
Neutropenia Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm

Symptoms & Phenotypes for Plasma Cell Neoplasm

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 B2M CD19 CD38 CD79A IL6 MPC1
2 hematopoietic system MP:0005397 9.9 B2M CD19 CD38 CD79A IL6 MAEA
3 digestive/alimentary MP:0005381 9.8 B2M CD19 IL6 MYC NSD2 PCSK5
4 immune system MP:0005387 9.7 B2M CD19 CD38 CD79A IL6 MAEA
5 neoplasm MP:0002006 9.17 B2M CD19 CD79A IL6 MYC PTPRC

Drugs & Therapeutics for Plasma Cell Neoplasm

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
2
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
3
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
4
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
5
Pomalyst 18 49 POMALIDOMIDE Celgene February 2013
6
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
7
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
8
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
9
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 714)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
5
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
6
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
8
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
10
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
11
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
12
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
13
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
14
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
15
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
16
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
17
Daratumumab Approved Phase 4,Phase 2,Phase 3,Phase 1 945721-28-8
18
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
19
Phentolamine Approved Phase 4 50-60-2 5775
20
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
21 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
22
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
23
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
24
Liraglutide Approved Phase 4 204656-20-2 44147092
25
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
26
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
27
Pirarubicin Investigational Phase 4 72496-41-4
28
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
29 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2636)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
2 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
3 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
4 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
5 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
6 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
7 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
8 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
9 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
10 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
11 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
12 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
13 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
15 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
16 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
17 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
18 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
19 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
20 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
21 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
22 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
23 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
24 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
25 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Active, not recruiting NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
26 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
27 A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Not yet recruiting NCT03768960 Phase 4 Daratumumab
28 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4 Plerixafor
29 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
30 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
31 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
32 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
33 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
34 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
35 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
36 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
37 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
38 High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
39 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
40 CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
41 Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
42 CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
43 MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation Unknown status NCT00256776 Phase 3 Velcade (Bortezomib);Thalidomide;Dexamethasone
44 Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs Unknown status NCT02066454 Phase 3 Apixaban
45 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
46 Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy Unknown status NCT00571168 Phase 3 Emend;Placebo
47 VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) Unknown status NCT01134484 Phase 3 Velcade;Thalidomide;Dexamethasone
48 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
49 Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years Unknown status NCT01532856 Phase 3 Thalidomide, Cyclophosphamide, Dexamethasone;Thalidomide, Dexamethasone;Thalidomide, Melphalan, Prednisone
50 Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: paraproteinemias

Genetic Tests for Plasma Cell Neoplasm

Anatomical Context for Plasma Cell Neoplasm

MalaCards organs/tissues related to Plasma Cell Neoplasm:

41
Bone, T Cells, Bone Marrow, B Cells, Neutrophil, Liver, Lung

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 168)
# Title Authors Year
1
Thymic plasma cell neoplasm infiltration in SjAPgren's syndrome with monoclonal gammopathy. ( 29590476 )
2018
2
Crystal-Storing Histiocytosis with Plasma Cell Neoplasm in the Setting of Chronic Carbamazepine Exposure. ( 29874901 )
2018
3
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. ( 30327369 )
2018
4
Aberrant T-cell antigen expression in a plasma cell neoplasm. ( 30026303 )
2018
5
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. ( 30348186 )
2018
6
TEMPI Syndrome: Erythrocytosis in Plasma Cell Dyscrasia. ( 30100329 )
2018
7
Normolipemic Xanthomas in a Patient with Underlying Plasma Cell Dyscrasia. ( 30369753 )
2018
8
Corrigendum to "Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship?" [Urology Case Reports 6 (2017) 50-52]. ( 29541578 )
2017
9
Plasma cell neoplasm as a risk factor for early thrombosis of arteriovenous fistula. ( 28762615 )
2017
10
Aberrant CD3 Expression in a Relapsed Plasma Cell Neoplasm. ( 29268594 )
2017
11
Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia. ( 28057674 )
2017
12
Cutaneous Vasculitis: An Unusual Presentation of a Biclonal Nodal Plasma Cell Dyscrasia. ( 29057130 )
2017
13
Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship? ( 27175345 )
2016
14
Plasma Cell Neoplasm Manifesting Initially as a Sub-Cutaneous Supra-Orbital Swelling. ( 26955130 )
2016
15
Cytology of plasma cell rich effusion in cases of plasma cell neoplasm. ( 27756988 )
2016
16
Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. ( 26796980 )
2016
17
Dual CD3 and CD4 positive plasma cell neoplasm with indistinct morphology: a diagnostic pitfall. ( 27133529 )
2016
18
Hematopoietic Cell and Renal Transplantation in Plasma Cell Dyscrasia Patients. ( 26160700 )
2016
19
Skin manifestations of POEMS and AESOP syndrome in the same patient revealing plasma cell dyscrasia. ( 27531391 )
2016
20
Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains. ( 26339430 )
2015
21
Osseous plasma cell neoplasm of the mandible for initial diagnosis of multiple myeloma: case report and literature review. ( 25861199 )
2015
22
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. ( 25851555 )
2015
23
A single-center case series of eight patients with the rare plasma cell dyscrasia of acquired Fanconi syndrome secondary to monoclonal gammopathy. ( 25791236 )
2015
24
Comparison of Hevylite™ IgA and IgG assay with conventional techniques for the diagnosis and follow-up of plasma cell dyscrasia. ( 25468997 )
2015
25
Nodal involvement of extranodal marginal zone lymphoma with extreme plasmacytic differentiation (Mott cell formation) simulating plasma cell neoplasm and lymphoplasmacytic lymphoma. ( 25548763 )
2014
26
Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow. ( 24395190 )
2014
27
Image of the month : a rare presentation of a plasma cell neoplasm. ( 25333092 )
2014
28
Epstein-Barr virus-driven bone marrow aplasia and plasmacytosis mimicking a plasma cell neoplasm. ( 24405048 )
2014
29
Crystal-storing histiocytosis with IgD I_-associated plasma cell neoplasm. ( 25028748 )
2014
30
Classical Hodgkin lymphoma with coexistant plasma cell neoplasm: A case report. ( 25308039 )
2014
31
Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. ( 24220620 )
2014
32
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. ( 25037886 )
2014
33
Intracellular and extracellular immunoglobulin crystals assuming a multitude of geometric shapes in an IgG-I> plasma cell neoplasm. ( 23720061 )
2013
34
Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm. ( 23814762 )
2013
35
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2013
36
Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia. ( 23217011 )
2013
37
Clinical challenges of an oligosecretory plasma cell dyscrasia. ( 23420725 )
2013
38
Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives. ( 23633539 )
2013
39
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. ( 22774220 )
2012
40
CD3 expression in plasma cell neoplasm (multiple myeloma): a diagnostic pitfall. ( 23172088 )
2012
41
Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH. ( 22658896 )
2012
42
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. ( 22429092 )
2012
43
Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey. ( 21851219 )
2011
44
Plasma cell neoplasm in conjunction with glioblastoma of the conus medullaris. ( 21325257 )
2011
45
Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. ( 20662075 )
2010
46
Mandibular radiolucency. Plasma cell neoplasm. ( 19906620 )
2009
47
Ophthalmic presentation of plasma cell neoplasm. ( 19617795 )
2009
48
Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect". ( 19176361 )
2009
49
Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment. ( 19215792 )
2009
50
Plasma cell dyscrasia presenting as ascites and omental mass. ( 18323560 )
2008

Variations for Plasma Cell Neoplasm

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Pathways for Plasma Cell Neoplasm

GO Terms for Plasma Cell Neoplasm

Cellular components related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 B2M CD38 NCAM1 PTPRC SDC1
2 external side of plasma membrane GO:0009897 9.1 B2M CD19 CD79A NCAM1 PTPRC SDC1

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of T cell mediated cytotoxicity GO:0001916 9.32 B2M PTPRC
2 positive regulation of glial cell proliferation GO:0060252 9.26 IL6 MYC
3 negative regulation of bone resorption GO:0045779 9.16 CD38 IL6
4 negative regulation of neuron projection development GO:0010977 9.13 B2M CD38 MAG
5 B cell receptor signaling pathway GO:0050853 8.92 CD19 CD38 CD79A PTPRC

Sources for Plasma Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....